These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 32670880)

  • 1. Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer.
    Quagliano A; Gopalakrishnapillai A; Barwe SP
    Front Oncol; 2020; 10():992. PubMed ID: 32670880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenomics in stress tolerance of plants under the climate change.
    Kumar M; Rani K
    Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
    Xu QY; Yu L
    Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets.
    Bajbouj K; Al-Ali A; Ramakrishnan RK; Saber-Ayad M; Hamid Q
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
    Singh D; Khan MA; Siddique HR
    Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.
    Facciotto C; Casado J; Turunen L; Leivonen SK; Tumiati M; Rantanen V; Kauppi L; Lehtonen R; Leppä S; Wennerberg K; Hautaniemi S
    Clin Epigenetics; 2019 Dec; 11(1):192. PubMed ID: 31829282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.
    Matthews BG; Bowden NA; Wong-Brown MW
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.
    Madkour MM; Ramadan WS; Saleh E; El-Awady R
    Ann Med; 2023 Dec; 55(1):2203946. PubMed ID: 37092854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
    Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.
    Gracia-Hernandez M; Munoz Z; Villagra A
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
    Bewersdorf JP; Shallis R; Stahl M; Zeidan AM
    Ther Adv Hematol; 2019; 10():2040620718816698. PubMed ID: 30719265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Chromatin Remodeling for Cancer Therapy.
    Kaur J; Daoud A; Eblen ST
    Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An insight into understanding the coupling between homologous recombination mediated DNA repair and chromatin remodeling mechanisms in plant genome: an update.
    Banerjee S; Roy S
    Cell Cycle; 2021 Sep; 20(18):1760-1784. PubMed ID: 34437813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
    Yeon M; Kim Y; Jung HS; Jeoung D
    Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
    Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
    Saleh R; Toor SM; Sasidharan Nair V; Elkord E
    Front Immunol; 2020; 11():1469. PubMed ID: 32760400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Epigenetic Cancer Therapeutics.
    Hillyar C; Rallis KS; Varghese J
    Cureus; 2020 Nov; 12(11):e11725. PubMed ID: 33391954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance.
    Fatma H; Maurya SK; Siddique HR
    Semin Cancer Biol; 2022 Aug; 83():166-176. PubMed ID: 33220458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
    Jazirehi AR; Arle D
    Am J Clin Exp Immunol; 2013; 2(1):55-74. PubMed ID: 23885325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.